An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-Negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen.

Trial Profile

An Open Label Phase II Trial to Assess the Efficacy and Safety of a Once Daily Oral Dose of 50 mg BIBW 2992 in Two Cohorts of Patients With HER2-Negative Metastatic Breast Cancer After Failure of no More Than Two Chemotherapy Regimen.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2013

At a glance

  • Drugs Afatinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
    • 12 Jul 2011 EudraCT reports actual initiation date 31 Oct 2006, actual end date is 31 Jan 2009, trial status is discontinued.
    • 02 Jun 2009 Planned number of patients changed from 60 to 50 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top